Novavax, Inc. (BMV:NVAX)

Market Cap	27.51B
Revenue (ttm)	14.21B
Net Income (ttm)	-3.91B
Shares Out	n/a
EPS (ttm)	-25.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,578
Average Volume	897
Open	155.00
Previous Close	145.00
Day's Range	155.00 - 171.00
52-Week Range	69.00 - 390.00
Beta	n/a
RSI	51.98
Earnings Date	Feb 28, 2025

About Novavax

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand n...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 1,543
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: NVAX

Financial Performance

In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.

Financial numbers in USD